Copanlisib + Letrozole + Palbociclib
Phase 1TerminatedDevelopment Stage
Estrogen Receptor Positive
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Aug 2, 2017 → Mar 31, 2022
About Copanlisib + Letrozole + Palbociclib
Copanlisib + Letrozole + Palbociclib is a phase 1 stage product being developed by Bayer for Estrogen Receptor Positive. The current trial status is terminated. This product is registered under clinical trial identifier NCT03128619. Target conditions include Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03128619 | Phase 1 | Terminated |
Competing Products
20 competing products in Estrogen Receptor Positive